- Home
- > Media & Investors
- > Media Relations
- > Press Releases
Press Releases
-
2020.08.31
PDF (160KB)
- Daiichi Sankyo Selected for AMED’s “Development of a Vaccine for COVID-19 Vaccines (Second Round)”
-
2020.08.31
PDF (214KB)
- Daiichi Sankyo Announces Results of Phase 3 Clinical Trial for Anticoagulant Edoxaban (ELDERCARE-AF Study)
-
2020.08.07
PDF (160KB)
- Daiichi Sankyo Selected as Provider for Japanese Government’s “Emergent Initiative to Build Production Capacity for COVID-19 Vaccines (First Round)”
-
2020.08.07
PDF (143KB)
- Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
-
2020.07.27
PDF (269KB)
- Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
-
2020.07.22
PDF (178KB)
- Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan
-
2020.07.21
PDF (153KB)
- Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients
-
2020.07.10
PDF (155KB)
- Daiichi Sankyo Announces Participation in AMR Action Fund
-
2020.07.07
PDF (151KB)
- EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer
-
2020.07.02
PDF (166KB)
- Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer
-
2020.06.29
PDF (166KB)
- Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT
-
2020.06.26
PDF (158KB)
- Daiichi Sankyo Announces Start of Discussions with AstraZeneca Regarding Supply in Japan of Novel Corona Virus Vaccine
-
2020.06.12
PDF (159KB)
- Daiichi Sankyo Announces Decision to Develop Vaccine in Japan for Novel Corona Virus Infection (COVID-19)
-
2020.06.08
PDF (142KB)
- The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19)
-
2020.06.01
PDF (309KB)
- ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
-
2020.06.01
PDF (288KB)
- ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
-
2020.06.01
PDF (319KB)
- ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial
-
2020.06.01
PDF (190KB)
- Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
-
2020.05.25
PDF (231KB)
- Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
-
2020.05.22
PDF (188KB)
- Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute
-
2020.05.22
PDF (186KB)
- ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
-
2020.05.18
PDF (184KB)
- ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
-
2020.05.11
PDF (195KB)
- ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer
-
2020.05.11
PDF (198KB)
- Daiichi Sankyo Announces Changes to Representative Directors and Members of the Board
-
2020.05.07
PDF (252KB)
- Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
-
2020.04.27
PDF (179KB)
- Daiichi Sankyo Announces Removal of Contaminated Soil Storage Facility from Site of Former Yasugawa Plant in Japan
-
2020.04.27
PDF (203KB)
- Daiichi Sankyo Announces Share Split, Partial Amendment to the Articles of Incorporation, and Forecast of Annual Dividend per Share for the Year Ending March 31, 2021
-
2020.04.14
PDF (160KB)
- Daiichi Sankyo Contributes to Relief Efforts for Countermeasures against COVID-19
-
2020.04.13
PDF (175KB)
- Daiichi Sankyo, Mitsubishi UFJ Capital and Nagoya Institute of Technology Announce Open Innovation Research on Gene Therapy to Restore Vision
-
2020.04.01
PDF (161KB)
- Daiichi Sankyo Enters into Strategic Partnership with Ultragenyx for Use of Gene Therapy Manufacturing Technology
-
2020.03.30
PDF (174KB)
- Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan
-
2020.03.27
PDF (149KB)
- Daiichi Sankyo and Kitasato Pharmaceutical Industry to End Sales Cooperation for Influenza HA Vaccine “Daiichi Sankyo” in Japan
-
2020.03.25
PDF (271KB)
- ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
-
2020.02.27
PDF (111KB)
- Anti-epilepsy Drug VIMPAT ®, Submission for Supplemental Application for Approval in Japan
-
2020.02.21
PDF (119KB)
- Daiichi Sankyo Appoints New Corporate Officers
-
2020.01.27
PDF (77KB)
- Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
-
2020.01.07
PDF (244KB)
- ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens
In order to view the PDF files, you need to have the latest version of Adobe Reader installed.
